Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 12 of 12, showing 4 Applications out of 59 total, starting on record 56, ending on 59

# Protocol No Study Title Investigator(s) & Site(s)

56.

ECCT/20/07/02   RV 460 HIV Vaccine Trial
    A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of   Priming with Env-C Plasmid DNA Vaccine Alone, with Different Adjuvants, or with an   Adjuvanted HIV Env gp145 C.6980 Protein Vaccine and Boosting with the Adjuvanted   HIV Env gp145 C.6980 Protein Vaccine with or without the Env-C Plasmid DNA Vaccine   in Healthy HIV Uninfected Adults in Kenya   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI/US MRDA-A/K, KERICHO
 
View

57.

ECCT/23/09/02   CROSSWALK Acute (A)
    A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD)   
Principal Investigator(s)
1. Doreen Terry Karimi
Site(s) in Kenya
Gertrudes Childrens Hospital
 
View

58.

ECCT/22/09/03   SINGLE DOSE VERSUS EXTENDED DO
    EFFECTIVENESS OFSINGLE-DOSE ANTIBIOTIC USE IN ELECTIVE CAESAREANSECTION IN PREVENTION OF SURGICAL SITE INFECTION AT JARAMOGI    OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL, KISUMU COUNTY,KENYA: A RANDOMIZED CONTROL TRIAL.   
Principal Investigator(s)
1. STEVEN ODHIAMBO JUMA
Site(s) in Kenya
JARAMOGI OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL
 
View

59.

ECCT/14/11/01   ZEBOV Trial
      A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya.                
Principal Investigator(s)
1. Philip Bejon
2. Patricia Njuguna
Site(s) in Kenya
KEMRI Wellcome Trust Research Programme
 
View